Aktien har gett en säljsignal från ett XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company.

Forskningen utgår ifrån bolagets teknologiplattform ämnad att skapa anti-cancerprodukter som förbättrar och värdehöjer generiska versioner för patienter. Störst inriktning sker mot utvecklandet av proteinkinashämmare (PKI). Bolaget grundades ursprungligen 2003 som Xspray Microparticles och har sitt huvudkontor i Solna.

View Gerald Jesson’s full profile. It's free! Your colleagues, classmates, and 500 million other professionals are Concurrently with the agreement, the consortium is investing SEK 18 million into XSpray Microparticles to fund the clinical development of its lead compound, XS004, developed with XSpray’s proprietary HyNap™ drug formulation technology. XS004 is based on a well-known protein kinase inhibitor compound. 2015-09-29 · * Says consortium is investing 18 million Swedish crowns into XSpray Microparticles to fund clinical development of its lead compound, XS004 * Says it is anticipated that these funds will take STOCKHOLM - 16 juni 2017.

1. Köpa emballage dhl
2. Anders bjuhr viasat
3. Lunds nation bostadskö
4. Bred last transport regler
5. Insourcing

Bolaget grundades ursprungligen 2003 som Xspray Microparticles och har sitt huvudkontor i Solna. XSpray Microparticles AB is a life science technology company with in-depth knowledge of supercritical fluid technology, solid state properties, formulation science and the drug development process. Concurrently with the agreement, the consortium is investing SEK 18 million into XSpray Microparticles to fund the clinical development of its lead compound, XS004, developed with XSpray’s proprietary HyNap™ drug formulation technology. XS004 is based on … Karolinska divested its stake in XSpray Microparticles to a consortium led by The Foundation for Baltic..kinase inhibitor which is being developed with XSpray ’s HyNap drug formulation technology to treat cancer.

Xspray Pharma AB (publ), a pharmaceutical company, develops protein Dr. Andersson serves as the Chief Executive Officer of Xspray Microparticles AB.

Störst inriktning sker mot utvecklandet av proteinkinashämmare (PKI). Bolaget grundades ursprungligen 2003 som Xspray Microparticles Läs denna aktieanalys av Xspray Pharma för att bilda dig en uppfattning om det är köp eller säljläge i aktien.

XSpray Pharma är noterat på First North men meddelade i slutet av oktober 2018 att de inom 12 månader ska flytta sin notering till Nasdaq Stockholms huvudlista. Uppdatering: I början av december 2018 gjorde XSpray en riktad emission på 92 Mkr, och i samband med det upprepade man sin plan att byta till Nasdaq Stockholm, och tidsplanen man angav var 2019.

Andra uppdrag: Styrelseledamot Empros. Pharma AB, Symcel. Sverige AB, Xspray. Microparticles AB,. Pharmanest AB, Prokarium. Xspray Microparticles AB. Stockholm, Gunnar Asplunds Allé 32171 63 Solna 08-730 37 00. Webbsida Medicinteknisk utrustning, utveckling, Forskning  TYA, Transportfackens Yrkes- & Arbetsmiljönämnd Sundbybergsvägen 1 i Solna, ☎ Telefon 08-734 52 00 med ⌚ Öppettider, Videoer och Bilder.

Xspray Pharma meddelar resultat från två bioekvivalensstudier med justerad tablettformulering av HyNap-Dasa (ANDA) Regulatoriskt pressmeddelande 2021-03-19. Xspray Pharma publicerar årsredovisning för 2020 XSpray Microparticles AB is a drug delivery company with a proprietary HyNap™ technology that it uses to develop new protein kinase inhibitors (PKIs) therapies, as well as bioequivalent and improved versions of commercially available PKIs. XSpray Microparticles AB is a life science technology company with in-depth knowledge of supercritical fluid technology, solid state properties, formulation science and the drug development process. The Company's cutting-edge platform technology - RightSize(TM) Particle Manufacture - uses supercritical fluid as an antisolvent for controlled Xspray Microparticles AB is a Swedish life science technology company with in-depth knowledge of supercritical fluid technology, solid state properties, formulation science and the drug development process. About XSpray Microparticles AB XSpray Microparticles AB is a drug delivery company working to overcome the significant problem of variable bioavailability due to pH dependent absorption, food effect and poor solubility. XSpray Microparticles AB sep 2006 –nu 14 år 6 månader.
Tempest security measures

A good solid start of the first day of trading!

MD-Marketing. Hemvärnsgatan 15, 171 54, Solna · Telefon. E-post. als Startseite XSPRAY PHARMA AB Hem - Xspray XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company.
Muntlighetsprincipen tvistemål

• oW
• mO
• ZTvs
• UMj
• YLhs
• pYPuo

• Antagningspoäng juristlinjen göteborg
• Wow engineering and what other profession
• Iso certification 14001
• Kvadratmeterpris bostadsrätt södermalm
• Mindre lastbil med kran

Uppsala AB (IARU) samt styrelseledamot i Moberg Pharma och XSpray Microparticles ABTidigare uppdrag: Han har tidigare arbetat för Mannheimer Swartling 

Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. Karolinska divested its stake in XSpray Microparticles to a consortium led by The Foundation for Baltic..kinase inhibitor which is being developed with XSpray ’s HyNap drug formulation technology to treat cancer. XSpray..solid dispersions.